Bernard Hudson profile

Bernard Hudson

A/Prof Bernard Hudson has over 30 years of experience in the fields of infectious diseases and clinical microbiology, as a clinician (physician: FRACP) and pathologist (microbiologist: FRCPA). He also holds specialist qualifications in public health (FAFPHM). He is currently Director of Clinical Microbiology and Infectious Diseases at Royal North Shore Hospital (RNSH) and has been since 2016. A/Prof Hudson oversees the clinical infectious diseases service for RNSH as well as the district-wide service for Northern Sydney Local Health District (NSLHD) and the Clinical Microbiology laboratory at RNSH in his capacity as supervising pathologist (microbiology) for that laboratory. His duties include oversight of all microbiology tests performed on site, including molecular biology, serology, bacteriology, mycobacteriology and mycology. He is responsible for the professional development and training of the division’s consultants, interns and registrars. Microbiology and Infectious Diseases have many links with other clinical specialties. It receives invaluable clinical samples that can be a valuable resource for collaborative research. Since 2018, A/Prof Hudson has collaborated with Professor Holmes at Sydney University in the search for novel pathogens in animals and humans. Most significant peer reviewed publications in the last 5 years: Prof Hudson has represented RNSH-NSLHD and NSW Health Pathology (NSWHP) as an institutional leader and Principal Investigator in multi-disciplinary projects. He has been the main contributor and subject matter expert reviewer of the data published. 1.       Balachandran H., Phetsouphanh C., Agapiou D….Hudson B., … Bull RA., on Behalf of the COSIN Study Group. Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses. Cell Reports 38, 110345, February 8, 2022

2.       Abayasingam A., Balachandran H., Agapiou D….Hudson B., Bull RA., on Behalf of the COSIN Study Group. Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection; Cell Reports Medicine (2021), https://doi.org/10.1016/j.xcrm.2021.100228. 3.       Shiel E, Miyakis S, Tennant E, Fernando S, Kizny-Gordon A, Koh B, Findlay M, Garnham K, Pilli S, Segboer H, Tallon J, Kao J, Miller A, Shore T, Maher R, Telford M, Barclay K, Harris B, Newcombe J, Hudson B, Figtree M. Clinical Characteristics and Outcomes of COVID-19 in a low-prevalence, well-resourced setting Internal Medicine Journal. 2021 Jul 06. [Journal Article] [2021/07/06 13:29]. 4.       Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection. Abayasingam A, Balachandran H, Agapiou D, Hammoud M, Rodrigo C, Keoshkerian E, Li H, Brasher NA, Christ D, Rouet R, Burnet D, Grubor-Bauk B, Rawlinson W, Turville S, Aggarwal A, Stella AO, Fichter C, Brilot F, Mina M, Post JJ, Hudson B, Gilroy N, Dwyer D, Sasson SC, Tea F, Pilli D, Kelleher A, Tedla N, Lloyd AR, Martinello M, Bull RA, COSIN Study Group. Cell Reports Medicine. 2(4):100228, 2021 Apr 20. [Journal Article] [2021/03/22 08:31]. 5.       Beukers AG, Newton P, Hudson B, Ross K, Gottlieb T, O'Sullivan M, Daley DA, Pang S, Coombs GW, van Hal SJ.A multicentre outbreak of ST45 MRSA containing deletions in the spa gene in New South Wales, Australia. Journal of Antimicrobial Chemotherapy. 75(5):1112-1116, 2020 05 01. [Journal Article. Multicenter Study] [2020/02/05 06:00]. 6.       Contamination of the Surgical Field with Propionibacterium acnes in Primary Shoulder Arthroplasty. Falconer TM, Baba M, Kruse LM, Dorrestijn O, Donaldson MJ, Smith MM, Figtree MC, Hudson BJ, Cass B, Young AA. Journal of Bone & Joint Surgery - American Volume. 98(20):1722-1728, 2016 Oct 19. [Journal Article] [2016/11/22 06:00]. 7.       Identification of a Novel Equine Papillomavirus in Semen from a Thoroughbred Stallion with a Penile Lesion. Li CX, Chang WS, Mitsakos K, Rodger J, Holmes EC, Hudson BJ Viruses. 11(8), 2019 08 04. [Journal Article. Research Support, Non-U.S. Gov't] [2019/08/07 06:00] UI: 31382657. **_Research Impact and Support: _**In 2020, A/Prof Hudson has established the first ever Infectious Diseases Clinical Research Unit at Royal North Shore Hospital. This Unit has attracted over $1.25 million in funding for investigation of patients with tickborne disease, using cutting edge genomic and biomarker techniques. Since onset of the SARS-2-CoV/COVID-19 pandemic, the RNSH Microbiology laboratory is consistently in the top 4 government laboratories in NSW by volume for SARS-2-CoV PCR tests performed. A/Prof Hudson is the laboratory expert member of NSLHD COVID-19 Executive and RNSH COVID-19 Executive and co-chair of NSLHD COVID-19 Research Committee, the major steering committees for NSLHD and RNSH during the pandemic.  1.       F2G Study (2021-Current): A Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with invasive fungal disease (IFD) caused by Aspergillus species Role: Global Clinical Trials Program Manager and NSWLHD-NSWHP North Coordinating Principal Investigator. 2.       ARMATA AP-SA02 (2021-Current): Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP-SA02 as an Adjunct to Best Available Antibiotic Therapy Compared to Best Available Antibiotic Therapy Alone for the Treatment of Adults With Bacteremia Due to Staphylococcus aureus Role: Global Clinical Trials Program Manager and NSLHD-NSWHP North Principal Investigator. 3.       Oncology Study (2021-Current): Immune response to COVID vaccination in patients with malignancy. Multicentre Clinical Trials NSLHD-NSWHP  North Principal Coordinator. 4.       COVID & HCW (2021-2021): Impacts of COVID-19 on NSW Health Care Workers. Clinical Trials Principal Coordinator. 5.       Prevalence of Asymptomatic SARS-Cov-2 Infection in Elective Surgical Patients in Australia. Multicentre study (2020-2021). Clinical Trials NSWHP North Principal Investigator. 6.       COVID-19 & Biomarker study (2021-2022): Identification of new biomarkers for severity, disease progression and response to treatment for COVID-19. Multicentre Clinical Trials NSWHP North Principal Coordinator. 7.       Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial: Multicentre Clinical Trials NSLHD-NSWHP Principal Investigator. 8.       COSIN Study (2020-2022) - Snow Medical Research Foundation: A national biobank of highly characterised samples from symptomatic and asymptomatic COVID-19 positive individuals, jointly led by a national consortium of researchers from the University of Melbourne, UNSW and The University of Sydney. NSLHD-NSWHP North Principal Investigator. 9.       Clinical and Laboratory Findings in Patients with Tickborne Diseases (2021-2026) - Snow Medical Research Foundation - Vectorborne Disease Clinical Research Centre Royal North Shore Hospital Northern Sydney Local Health District, University of Sydney, Macquarie University. 10.    Single target LOW Positive for SARS-CoV-2 diagnosis (LOW-POS) (2020-Current). Principal Investigator. 11.    Improving diagnostics for detection of enterovirus outbreaks by collection and PCR of residual enterovirus-positive samples (2019-2026). NSLHD-NSWHP North Principal Investigator. 12.    Pathogen Discovery (2020-Ongoing) – SREI: Centre for Pathogen Discovery, Holmes E, Shi M, Eden J, Sintchenko V, Lo N, Barrs V, Beatty J, Hudson B, Rose K, Rockett R, DVC Research/Sydney Research Excellence Initiative 2020. 13.    Next Generation Sequencing for Detection of Tickborne Pathogens in Australia (2018-2021) – NHMRC: Using Metagenomics to Determine the Causative Agents of Tick-Borne Disease in Australia, Holmes E, Bunce M, Hudson B, Lo N, Hansen A, National Health and Medical Research Council (NHMRC)/Project Grants.NSLHD-NSWHP North Principal Investigator. National and International Scientific Recognition: A/Prof Hudson is the founding chair of the Travel Health Advisory Group (THAG) a peak body affiliated with the Australian College of Tropical Medicine that promotes safe and healthy travel to the community as well as sponsoring research studies in travel medicine and health. For over 20 years, A/Prof Hudson has lectured annually as a guest professor at the travel medicine block in the Master of Public Health program at James Cook University, Townsville. For over 10 years, he has also been an invited speaker at the Global Health Program at Sydney University and the Master of Infection and Immunology Program at Westmead Hospital/ICPMR. A/Prof Hudson has been a topic editor for Frontiers in Microbiology and has peer reviewed a number of papers for local and international journals.

https://www.sydney.edu.au/medicine-health/about/our-people/academic-staff/bernard-hudson.html https://www.ramsayhealth.com.au/Specialists/north-shore-private-hospital/infectious-diseases/102058/dr-bernard-hudson

© 2022 Phage Australia
svelte head: undefined